Sam Brusco, Associate Editor12.14.23
Calyxo, a company developing next-gen treatment solutions for kidney stones, has closed a $50 million Series D financing round headed by Avidity Partners, with participation from existing investors Questa Capital and CRG.
The company is commercializing the CVAC aspiration system, which leverages irrigation and aspiration to remove kidney stones with the aim of minimizing residual stone burden. The tech has already been used to successfully treat over 1,300 U.S. patients, Calyxo said.
“We are excited about this round of funding which will further accelerate the company’s momentum,” said Calyxo’s president and CEO Joe Catanese. “Despite the challenging market conditions, we received strong support from investors who believe in our team, our mission and the promise of our CVAC technology. Our kidney stone treatment innovations will improve care for patients and have the opportunity to transform the way this condition is treated. We will use this capital to build commercial traction while maintaining investment in product development and clinical studies.”
Avidity Partners’ Jacob Garfield will also join Calyxo’s board.
“We are proud to invest in Calyxo and its groundbreaking technology,” said Garfield. “Calyxo has an opportunity to alter the kidney stone treatment category and deliver a new generation of devices that can significantly improve care and comfort for millions of people afflicted by kidney stones. We look forward to working with the company’s leadership team as it seeks to accomplish its mission to provide a disruptive solution for a long-standing medical challenge.”
The company is commercializing the CVAC aspiration system, which leverages irrigation and aspiration to remove kidney stones with the aim of minimizing residual stone burden. The tech has already been used to successfully treat over 1,300 U.S. patients, Calyxo said.
“We are excited about this round of funding which will further accelerate the company’s momentum,” said Calyxo’s president and CEO Joe Catanese. “Despite the challenging market conditions, we received strong support from investors who believe in our team, our mission and the promise of our CVAC technology. Our kidney stone treatment innovations will improve care for patients and have the opportunity to transform the way this condition is treated. We will use this capital to build commercial traction while maintaining investment in product development and clinical studies.”
Avidity Partners’ Jacob Garfield will also join Calyxo’s board.
“We are proud to invest in Calyxo and its groundbreaking technology,” said Garfield. “Calyxo has an opportunity to alter the kidney stone treatment category and deliver a new generation of devices that can significantly improve care and comfort for millions of people afflicted by kidney stones. We look forward to working with the company’s leadership team as it seeks to accomplish its mission to provide a disruptive solution for a long-standing medical challenge.”